Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MLLCF MOLECULAR PARTNERS AG > Company Executives
MLLCF MOLECULAR PARTNERS AG
6.4500.0000.00%
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Patrick Amstutz, PhDChief Executive Officer and Director1.05M----46male03/15/2022
Dr. Nicolas Leupin, M.B.A.,M.D.Chief Medical Officer------48male03/15/2022
Dr. Michael Tobias Stumpp, PhDChief Operating Officer------49male03/15/2022
Mr. Andreas EmmeneggerChief Financial Officer------55male03/15/2022
Mr. William M. BurnsChairman of the Board295.00K----74male03/15/2022
Mr. Steven H. HoltzmanIndependent Director133.00K----68male03/15/2022
Dr. Vito J. Palombella, PhDIndependent Director125.00K----59male03/15/2022
Mr. Sandip S. Kapadia, C.P.A.,M.B.A.Independent Director130.00K----52male03/15/2022
Dr. Michael Vasconcelles, M.D.Independent Director133.00K----58male03/15/2022
Dr. Agnete Fredriksen, PhDIndependent Director113.00K----44female03/15/2022
Dr. Dominik Hochli, M.D.Independent Director113.00K----54male03/15/2022
Company Overview More
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
CEO: Dr. Patrick Amstutz, PhD
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist